For CLL, a bi-specific construct was tested that targets CD19 while recruiting NK cells via ULBP2 (UL16 binding protein 2, the ligand of the cytotoxic NKG2D receptor) [70]. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.